Cell-Free DNA As Peripheral Biomarker of Alzheimer’s Disease DOI Creative Commons
Sachi Khemka, Ujala Sehar, Pulak R. Manna

et al.

Aging and Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Alzheimer's disease (AD) and disease-related disorders (ADRD) are progressive neurodegenerative diseases without cure. occurs in 2 forms, early-onset familial AD late-onset sporadic AD. Early-onset is a rare (~1%), autosomal dominant, caused by mutations presenilin-1, presenilin-2, amyloid precursor protein genes the other late-onset, prevalent evolved due to age-associated complex interactions between environmental genetic factors, addition apolipoprotein E4 polymorphism. Cellular senescence, promoting impairment of physical mental functions constituted be main cause aging, primary risk factor for AD, which results loss cognitive function, memory, visual-spatial skills an individual live or act independently. Despite significant progress understanding biology pathophysiology we continue lack definitive early detectable biomarkers and/or drug targets that can used delay development ADRD elderly populations. However, recent developments studies DNA double-strand breaks result release fragmented into bloodstream contribute higher levels cell-free (cf-DNA). This cf-DNA released from various cell types, including normal cells undergoing apoptosis necrosis elevated blood have potential serve as blood-based biomarker detection ADRD. The overall goal our study discuss latest circulating progression Our article summarized status research on both healthy states how these develop also discussed impact lifestyle epigenetic factors involved

Language: Английский

Mismatch-Guided Deoxyribonucleic Acid Assembly Enables Ultrasensitive and Multiplex Detection of Low-Allele-Fraction Variants in Clinical Samples DOI

Dan Huang,

Hui Deng, Juan Zhou

et al.

Journal of the American Chemical Society, Journal Year: 2023, Volume and Issue: 145(37), P. 20412 - 20421

Published: Aug. 31, 2023

Somatic mutations are important signatures in clinical cancer treatment. However, accurate detection of rare somatic with low variant-allele frequencies (VAFs) samples is challenging because the interference caused by high concentrations wild-type (WT) sequences. Here, we report a post amplification SNV-specific DNA assembly (PANDA) technology that eliminates concentration pressure WT through mismatch-guided and enables ultrasensitive VAFs as 0.1%. Because it generates an product only exposes single-stranded domain minimal length for signal readout thus possible interferences from secondary structures cross-interactions among sequences, PANDA highly versatile expandable multiplex testing. With ultrahigh sensitivity, enabled quantitative analysis EGFR cell-free 68 plasma four pleuroperitoneal fluid samples, test results consistent NGS deep sequencing. Compared to digital PCR, returned fewer false negatives ambiguous cases tests. Meanwhile, also offers much lower upfront instrumental operational costs. The multiplexity was demonstrated developing 3-plex simultaneous three 54 pairs tumor adjacent noncancerous tissue collected lung patients. multiplexity, simplicity, anticipate will find wide applications analyzing clinically diverse devastating diseases.

Language: Английский

Citations

24
Artificial urinary biomarker probes for diagnosis DOI
Cheng Xu, Kanyi Pu

Nature Reviews Bioengineering, Journal Year: 2024, Volume and Issue: 2(5), P. 425 - 441

Published: Feb. 28, 2024

Language: Английский

Citations

13
Developing a nanomaterial-based 3D-printed platform: Application as a cancer aptasensor via detection of heat shock protein 90 (HSP90) DOI
Masoud Negahdary, Claudimir Lúcio do Lago, Ivano Gebhardt Rolf Gutz

et al.

Sensors and Actuators B Chemical, Journal Year: 2024, Volume and Issue: 409, P. 135592 - 135592

Published: March 4, 2024

Language: Английский

Citations

13
Circulating Tumor DNA and Survival in Metastatic Breast Cancer DOI Creative Commons
Kyle Dickinson,

Archi Sharma,

Ramanakumar V. Agnihotram

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(9), P. e2431722 - e2431722

Published: Sept. 5, 2024

Importance Metastatic breast cancer (MBC) poses a substantial clinical challenge despite advancements in diagnosis and treatment. While tissue biopsies offer static snapshot of disease, liquid biopsy—through detection circulating tumor DNA (ctDNA)—provides minimally invasive, real-time insight into biology. Objective To determine the association between ctDNA survival outcomes patients with MBC. Data Sources An electronic search was performed 5 databases (CINAHL, Cochrane Library, Embase, Medline, Web Science) included all articles published from inception until October 23, 2023. Study Selection be meta-analysis, studies had to (1) include women diagnosed MBC; (2) report baseline plasma data; (3) overall survival, progression-free or disease-free associated hazards ratios. Extraction Synthesis Titles abstracts were screened independently by 2 authors. pooled using random-effects model. This study adhered Preferred Reporting Items for Systematic Reviews Meta-analyses ( PRISMA ) reporting guideline, quality assessed Newcastle-Ottawa Scale. Main Outcomes Measures The primary outcome specific genomic alterations outcomes. Secondary objectives associations methodology survival. Results Of 3162 reviewed, 37 met inclusion criteria reported data 4264 female aged 20 94 years. Aggregated analysis revealed significant worse (hazard ratio, 1.40; 95% CI, 1.22-1.58). Subgroup identified TP53 ESR1 ratios, 1.58 [95% 1.34-1.81] 1.28 0.96-1.60], respectively), while PIK3CA not Stratifying method, through next-generation sequencing digital polymerase chain reaction 1.48 1.22-1.74] 1.05-1.50], respectively). Conclusions Relevance In this systematic review overall, progression-free, suggesting its potential as prognostic biomarker These results may help guide design future actionability findings.

Language: Английский

Citations

13
Development of new techniques and clinical applications of liquid biopsy in lung cancer management DOI Creative Commons
Kezhong Chen, Yue He,

Wenxiang Wang

et al.

Science Bulletin, Journal Year: 2024, Volume and Issue: 69(10), P. 1556 - 1568

Published: April 1, 2024

Lung cancer is an exceedingly malignant tumor reported as having the highest morbidity and mortality of any worldwide, thus posing a great threat to global health. Despite growing demand for precision medicine, current methods early clinical detection, treatment prognosis monitoring in lung are hampered by certain bottlenecks. Studies have found that during formation development tumor, molecular substances carrying tumor-related genetic information can be released into body fluids. Liquid biopsy (LB), method detecting these markers fluids, may way make progress In recent years, LB technology has undergone rapid advancements. Therefore, this review will provide on technical updates its potential applications, evaluate effectiveness specific discuss existing limitations LB, present look forward possible future applications. Specifically, paper introduce from prospectives engineering breakthroughs detection membrane-based biomarkers other improvements sequencing technology. Additionally, it summarize latest applications liquid diagnosis, treatment, among cancer. We interconnectedness laboratory issues interplay application today.

Language: Английский

Citations

11
Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies DOI
Tali Pomerantz, Rebecca Brooks

Current Treatment Options in Oncology, Journal Year: 2024, Volume and Issue: 25(4), P. 510 - 522

Published: March 12, 2024

Language: Английский

Citations

10
5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation DOI Creative Commons

Danjun Song,

Zhou Zhang,

Jiaping Zheng

et al.

Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)

Published: March 7, 2025

Abstract Developing accurate, clinically convenient, and non-invasive methods for early cancer detection, monitoring, prognosis assessment is essential improving patient survival rates, enhancing quality of life, reducing the socioeconomic burden associated with cancer. This goal critical in precision oncology. Genetic epigenetic alterations circulating cell-free DNA (cfDNA) have emerged as transformative tools advancing outcomes. Among these, 5-hydroxymethylcytosine (5hmC) modifications cfDNA stand out promising markers, offering insights into initiation, progression, metastasis, across various types, such lung cancer, colorectal hepatocellular carcinoma. review comprehensively explores biology sequencing methodologies 5hmC, emphasizing their potential screening, diagnosis, treatment prognostic assessment. It highlights recent advancements cfDNA-derived 5hmC signatures’ applications, addressing strengths limitations context clinical translation. Furthermore, this outlines key challenges future directions integrating routine practice, facilitating personalized management.

Language: Английский

Citations

2
Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer DOI Creative Commons
Shijie Li,

Kerong Xin,

Shen Pan

et al.

Cellular & Molecular Biology Letters, Journal Year: 2023, Volume and Issue: 28(1)

Published: April 4, 2023

Abstract Bladder cancer (BC) is a clinical challenge worldwide with late presentation, poor prognosis, and low survival rates. Traditional cystoscopy tissue biopsy are routine methods for the diagnosis, monitoring of BC. However, due to heterogeneity limitations tumors, such as aggressiveness, high cost, limited applicability longitudinal surveillance, identification tumor markers has attracted significant attention in Over past decade, liquid biopsies (e.g., blood) have proven be highly efficient discovery BC biomarkers. This noninvasive sampling method used analyze unique components released into peripheral circulation allows serial progression. Several biomarkers being extensively studied shown promising results applications BC, including early detection, detection microscopic residual disease, prediction recurrence, response therapy. Therefore, this review, we aim provide an update on various novel blood-based review advantages current The role circulating cells, DNA, cell-free RNA, exosomes, metabolomics, proteomics treatment monitoring, their personalized management highlighted.

Language: Английский

Citations

20
Spatial tumor biopsy with fluorescence PCR microneedle array DOI Creative Commons
Xiaoxuan Zhang, Guopu Chen, Yu Wang

et al.

The Innovation, Journal Year: 2023, Volume and Issue: 5(1), P. 100538 - 100538

Published: Nov. 16, 2023

Biopsy is the gold standard for tumor diagnosis, as this technology provides highly detailed and reliable information on tumorigenesis progression. Resembling discrete wettability of desert beetles, in study, a fluorescence polymerase chain reaction (F-PCR) microneedle array (MNA) platform developed efficient spatial biopsy. This MNA fabricated by coupled strategies bottom-up self-assembly top-down photolithography; it comprises hydrophobic silica nanoparticle-assembled substrate graphene aerogel-hydrogel hybrid peaks. Benefitting from hydrophilicity absorption capacity its peaks, can easily penetrate tissue specimens collect nucleic acid biomarkers stereoscopically. In addition, because platform, both fluids PCR liquids be removed substrate, each peak similar to an independent island directly conducting F-PCR reactions marker discovery. Based these advantages, F-PCR-MNA demonstrated ideal detecting DNA lung carcinoma solutions, mouse samples, clinical specimens, thus indicating practical potential innovative biopsy system.

Language: Английский

Citations

18
Systematically Evaluating Cell‐Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns DOI Creative Commons
Yuying Hou, Xiangyu Meng, Xionghui Zhou

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(30)

Published: June 17, 2024

Cell-free DNA (cfDNA) fragmentation patterns have immense potential for early cancer detection. However, the definition of varies, ranging from entire genome to specific genomic regions. These not been systematically compared, impeding broader research and practical implementation. Here, 1382 plasma cfDNA sequencing samples 8 types are collected. Considering that within open chromatin regions is more susceptible fragmentation, 10 as features employed machine learning techniques evaluate their performance examined. All demonstrated discernible classification capabilities, with end motif showing highest diagnostic value cross-validation. Combining cross independent validation results revealed incorporated both fragment length coverage information exhibited robust predictive capacities. Despite potential, power these unstable. To address this limitation, an ensemble classifier via integrating all developed, which notable improvements in detection tissue-of-origin determination. Further functional bioinformatics investigations on significant feature intervals model its impressive ability identify critical regulatory involved pathogenesis.

Language: Английский

Citations

9